HemOnc Today Current Issue
The following articles appeared in the print edition of HemOnc Today.
Table of Contents
- Targeted agents trigger ‘paradigm shift’ in treatment of Hodgkin’s lymphoma
-
- Management of pancreatic neuroendocrine tumors remains ‘complex, challenging’ Leonard Saltz, MD
- Treatment of VTE: Warfarin and parenteral anticoagulation still have a role Jessica Mintz, MD; Michael R. Jaff, DO; Ido Weinberg, MD
- Better cancer care: My ‘one thing’ to learn more about this week John Sweetenham, MD, FRCP, FACP
- FDA expands approval of Opdivo for advanced squamous NSCLC
- Zarxio becomes first approved biosimilar in US
- FDA approves Unituxin for pediatric patients with high-risk neuroblastoma
- FDA fast tracks HS-410 for nonmuscle-invasive bladder cancer
- FDA grants breakthrough status to EBV-CTL for EBV-associated lymphoproliferative disease
-
- FDA grants orphan drug designation to entrectinib for colorectal cancer
- FDA grants orphan drug designation to Reolysin for fallopian tube cancer
- FDA grants orphan drug status to Factor Xa inhibitor antidote
- Neutrolin earns designation as qualified infectious disease product
- ADT increases risk for cardiovascular disease in men with prostate cancer
- Caregivers of patients with cancer often have unmet support needs
- Clinical, laboratory parameters predict early pancreatic adenocarcinoma mortality
- Direct oral anticoagulants appear safe for preventing cancer-related VTE
-
- EGFR L858R mutation in circulating free DNA linked to NSCLC outcomes
- Eight physical signs associated with impending death in patients with cancer
- Eltrombopag after romiplostim appears safe in treating ITP
- Exam of numerous tissues shows no significant difference in staging thin melanomas
- High fetal growth, family history increase risk for ALL
- Hospital type, patient age influence treatment of newly diagnosed myelodysplastic syndrome
- Inherited gene variant increases neuropathy risk in children with ALL
- Ipilimumab confers long-term survival in advanced melanoma
-
- Ipilimumab improves 5-year survival rate in advanced melanoma
- Maintenance sunitinib extends PFS in extensive-stage small cell lung cancer
- Marrow neoplasm risk increased after adjuvant breast cancer therapy
- Military protocol may benefit civilians in need of massive blood transfusion
- Mohs' micrographic surgery effective for primary mucinous carcinoma of skin
- NUDT15 variant linked to mercaptopurine intolerance in pediatric ALL
- Patient characteristics linked to degree of family involvement in treatment decisions
- Radiotherapy benefits good-risk patients with DCIS after breast-conserving surgery
-
- Self-collected HPV testing viable option for cervical cancer screening
- SLNB indicated for thick, clinically lymph node-negative melanoma
- Statin use may reduce risk for liver cancer
- Temsirolimus, bevacizumab shows promise for pancreatic neuroendocrine tumors
- Ultrasound may lead to less invasive surgery in lymph node-positive breast cancer
- Up to 25% of patients with papillary thyroid cancer may receive inappropriate radioactive iodine therapy
- Cancer center names director of clinical research
- Former NCI chief joins Weill Cornell
-
- Health network appoints director
- Mayo Clinic center makes appointment
- Oncology research network expands
- Active surveillance not appropriate for all patients with intermediate-risk prostate cancer
- VEGF inhibitors not effective for locally advanced kidney cancer